Rash rates with EGFR inhibitors: Meta-analysis

Current Oncology

Volumn 18, Issue 2, 2011, Pages

  Mittmann, N ^a   Seung, S J ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Epidermal growth factor receptor inhibitors; Metaanalysis; Rash

Indexed keywords

CAPECITABINE; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; NAVELBINE; OXALIPLATIN; PANITUMUMAB; PLATINUM COMPLEX;

ACNE; ARTICLE; COLORECTAL CANCER; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; HEAD AND NECK CANCER; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PANCREAS CANCER; RASH; SENSITIVITY ANALYSIS; SKIN EXFOLIATION; SKIN MANIFESTATION; SKIN TOXICITY; SYSTEMATIC REVIEW;

EID: 79955460505     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v18i2.605     Document Type: Article

References (48)

1. Adenis A, Aranda Aguilar E, Robin YM, et al. Expression of the epidermal growth factor receptor (EGFR or her1) and human epidermal growth factor receptor 2 (her2) in a large scale metastatic colorectal cancer (MCRC) trial [abstract 3630]. J Clin Oncol 2005;23:. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=34&abstractID=31696; cited January 31. 2011]
2. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002;62:7350-7356.
3. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002;94:1593-1611.
4. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase ii trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-1208.
5. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006;33:369-385.
6. Boone SL, Rademaker A, Liu D, Pfeiffer C, Mauro DJ, Lacouture ME. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 2007;72:152-159.
7. United States, Department of Health and Human Services, National Institutes of Health, National Cancer Institute (NCI). Common Terminology Criteria for Adverse Events (CTCAE). Ver. 4. Bethesda, MD: NCI; 2010. [Available online at: www.evs.nci. nih.gov/ftp1/CTCAE/About.html; cited January 31, 2011]
8. Molinari E, De Quatrebarbes J, Andre T, Aractingi S. Cetuximab- induced acne. Dermatology 2005;211:330-333.
9. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-2048.
10. Koutcher LD, Wolden S, Lee N. Severe radiation dermatitis in patients with locally advanced head and neck cancer treated with concurrent radiation and cetuximab. Am J Clin Oncol 2009;32:472-476.
11. Lacouture ME, Lai SE. The pride (papulopustules and/or paronychia, regulatory abnormalities of hair growth, itching, and dryness due to epidermal growth factor receptor inhibitors) syndrome. Br J Dermatol 2006;155:852-854.
12. Tejwani A, Wu S, Jia Y, Agulnik M, Millender L, Lacouture ME. Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor therapy. Cancer 2009;115:1286-1299.
13. Bourhis J, Rivera F, Mesia R, et al. Phase i/ii study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2006;24:2866-2872.
14. Peeters M, Siena S, Van Custem E, et al. Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer 2009;115:1544-1554.
15. Giusti RM, Shastri K, Pilaro AM, et al. U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Clin Cancer Res 2008;14:1296-1302.
16. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase iii randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005;23:8646-8654.
17. Butts CA, Bodkin D, Middleman EL, et al. Randomized phase ii study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J Clin Oncol 2007;25:5777-84. [Erratum in: J Clin Oncol 2008;26:3295]
18. Van Custem E, Peeters M, Siena S, et al. Open-label phase iii trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-1664.
19. Borner M, Koeberle D, Von Moos R, et al. Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase ii trial of the Swiss Group for Clinical Cancer Research SAKK. Ann Oncol 2008;19:1288-1292.
20. Cascinu S, Berardi R, Labianca R, et al. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase ii trial. Lancet Oncol 2008;9:39-44.
21. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase iii trial. Lancet 2009;373:1525-1531.
22. Rosell R, Robinet G, Szczesna A, et al. Randomized phase ii study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFRexpressing advanced non-small-cell lung cancer. Ann Oncol 2008;19:362-369.
23. Sobrero AF, Maurel J, Fehrenbacher L, et al. epic: phase iii trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:2311-2319.
24. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-1127.
25. Adams RA, Meade AM, Madi A, et al. Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC coin trial experience. Br J Cancer 2009;100:251-258.
26. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663-671.
27. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-1417.
28. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and NECK. N Engl J Med 2006;354:567-578.
29. Budach W, Bolke E, Homey B. Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Med 2007;357:514-515.
30. Giro C, Berger B, Bolke E, et al. High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes. Radiother Oncol 2009;90:166-171.
31. Lord HK, Junor E, Ironside J. Cetuximab is effective, but more toxic than reported in the Bonner trial. Clin Oncol (R Coll Radiol) 2008;20:96.
32. Pryor DI, Porceddu SV, Burmeister BH, et al. Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer. Radiother Oncol 2009;90:172-176.
33. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase iiib trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009;27:672-680.
34. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360:563-572.
35. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-4599.
36. International Federation of Pharmaceutical Manufacturers and Associations (ifpma). Medical Dictionary for Regulatory Activities (MedDra) [Web resource]. Ver. 12.0. Geneva, Switzerland: IFPMA; n.d. [Available online at: www.meddramsso.com; cited January 23, 2011]
37. Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 2009;4:107-119.
38. Perez-Soler R. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology (Williston Park) 2003;17(suppl 12):23-28.
39. Jatoi A, Nguyen DL. Do patients die from rashes from epidermal growth factor inhibitors? A systematic review to help counsel patients about holding therapy. Oncologist 2008:13:1201-1204.
40. Jatoi A, Rowland K, Sloan JA, et al. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 2008;113:847-853.
41. Wagner LI, Lacouture ME. Dermatologic toxicities associated with EGFR inhibitors: a clinical psychologist's perspective. Oncology (Williston Park) 2007;21(suppl 5):34-36.
42. Osio A, Matues C, Soria JC, et al. Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors. Br J Dermatol 2009;161:515-521.
43. Wagner LI, Beaumont JL, Ding B, et al. Measuring healthrelated quality of life and neutropenia-specific concerns among older adults undergoing chemotherapy: validation of the Functional Assessment of Cancer Therapy-Neutropenia (FACT-N). Support Care Cancer 2008;16:47-56.
44. Boland WK, Bebb G. Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity. Expert Opin Biol Ther 2009;9:1199-1206.
45. Lammerts van Bueren JJ, Bleeker WK, Brannstrome A, et al. The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular FLEXibility. Proc Natl Acad Sci U S A 2008;105:6109-114.
46. Melosky B, Burkes R, Rayson D, Alcindor T, Shear N, Lacouture M. Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Curr Oncol 2009;16:16-26.
47. Sipples R. Common side effects of anti-EGFR therapy: acneform rash. Semin Oncol Nurs 2006;22(suppl 1):28-34.
48. Decision Resources. Colorectal Cancer (Stage IV): Therapies Must Increase Overall Survival over IFL Plus Bevacizumab to Reach Blockbuster Status. DecisionBase Report. Burlington, MA: Decision Resources; 2008: 70-73.